If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Due to the neurotoxicity of its metabolite, norpethidine, it is more toxic than other opioids—especially during long-term use. The norpethidine metabolite was found to have serotonergic effects, so pethidine could, unlike most opioids, increase the risk of triggering serotonin syndrome.
Co-developed and co-marketed with Bayer, sorafenib—sold under the trade name Nexavar—is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007. Sorafenib has also been evaluated in other types of cancer, including thyroid (as a treatment of last resort) and breast (in comparison to capecitabine). In July 2014, the company announced the phase III failure of a Sorafenib-Capecitabine combination trial. The drug combination failed to increase progression free survival of patients with advanced breast cancer.
==== At the primary care level ==== Given the volume of care provided in primary care (general practice), recent strategies have focused on reducing unnecessary antimicrobial prescribing in this setting. Simple interventions, such as written information explaining when taking antibiotics is not necessary, for example in common infections of the upper respiratory tract, have been shown to reduce antibiotic prescribing. Various tools are also available to help professionals decide if prescribing antimicrobials is necessary. Parental expectations, driven by the worry for their children's health, can influence how often children are prescribed antibiotics. Parents often rely on their clinician for advice and reassurance. However a lack of plain language information and not having adequate time for consultation negatively impacts this relationship. In effect parents often rely on past experiences in their expectations rather than reassurance from the clinician. Adequate time for consultation and plain language information can help parents make informed decisions and avoid unnecessary antibiotic use. The prescriber should closely adhere to the five rights of drug administration: the right patient, the right drug, the right dose, the right route, and the right time. Microbiological samples should be taken for culture and sensitivity testing before treatment when indicated and treatment potentially changed based on the susceptibility report.
=== 1950s === In the 1950s, we saw innovation in technology across all fields, but most importantly there were many breakthroughs which led to modern medicine. On 6 March 1953, Dr. Jonas Salk announced the completion of the first successful killed-virus Polio vaccine. The vaccine was tested on about 1.6 million Canadian, American, and Finnish children in 1954. The vaccine was announced as safe on 12 April 1955. The 1950s saw foundational breakthroughs that reshaped modern molecular biology and clinical medicine. In 1953, James Watson and Francis Crick, drawing on the X-ray diffraction work of Rosalind Franklin and Maurice Wilkins, deduced the double-helix structure of DNA. In December 1953 at the Brigham Hospital in Boston, Dr. Joseph Murray performed the first successful human kidney transplant between identical twins. By 1958, Rune Elmqvist and Ake Senning developed and implanted the first fully internal cardiac pacemaker.
Sources: en.wikipedia.org
On some early frost-free models, the defrost limiter also sends a signal to the defrost timer to start the compressor and fan as soon as it shuts off the heating element before the timed defrost cycle ends. When the defrost cycle is completed, the compressor and fan are allowed to cycle back on. Frost-free refrigerators, including some early frost-free refrigerators/freezers that used a cold plate in their refrigerator section instead of airflow from the freezer section, generally don't shut off their refrigerator fans during defrosting. This allows consumers to leave food in the main refrigerator compartment uncovered, and also helps keep vegetables moist. This method also helps reduce energy consumption, because the refrigerator is above freeze point and can pass the warmer-than-freezing air through the evaporator or cold plate to aid the defrosting cycle.
=== BOC (1968-2006) === BOC Group's purchase of Edwards in 1968 was followed by international expansion, particularly into Asia, and investment at the Crawley, Eastbourne, Shoreham and Burgess Hill sites. In 1984, Edwards developed and patented the first practical high vacuum dry (no-oil) pump. The design was taken up by the fast-growing semiconductor manufacturing market. In 1992, Edwards purchased Electrotech Ltd's semiconductor manufacturing exhaust gas management systems. It was based in Nailsea before moving to Clevedon, UK to add to Edwards' semiconductor manufacturing environmental abatement technology. Four years later in 1996, new facilities in Burgess Hill are inaugurated. In 1997, BOC merged its electronics gases business with Edwards as BOC Edwards. In the same year, the company purchased Systems Chemistry Inc, a supplier of management systems for ultrapure chemicals used in semiconductor manufacturing, from Submicron Systems Corp of Allentown (USA). It became Edwards' chemical management division. Allentown, USA. It became Edwards' chemical management division. In 1999, Edwards acquired the Minneapolis-based division of FSI International Inc, for US$38 million. This was followed by the purchase of the Hick Hargreaves vacuum ejector and deaerator units; Wilhelm Klein GmbH; Stokes piston pump operations, and Hibon Inc for £12.8 million from Smiths Group. In 2002, they purchased Seiko Industry's turbomolecular pump manufacturing business for £70 million.
==== MeSH D13.695.667 – purine nucleotides ==== MeSH D13.695.667.138 – adenine nucleotides MeSH D13.695.667.138.124 – adenosine diphosphate MeSH D13.695.667.138.124.070 – adenosine diphosphate sugars MeSH D13.695.667.138.124.070.075 – adenosine diphosphate glucose MeSH D13.695.667.138.124.070.125 – adenosine diphosphate ribose MeSH D13.695.667.138.124.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.667.138.124.070.125.195 – cyclic adp-ribose MeSH D13.695.667.138.180 – adenosine monophosphate MeSH D13.695.667.138.180.080 – adenosine phosphosulfate MeSH D13.695.667.138.236 – adenosine triphosphate MeSH D13.695.667.138.236.050 – adenylyl imidodiphosphate MeSH D13.695.667.138.236.250 – ethenoadenosine triphosphate MeSH D13.695.667.138.382 – coenzyme a MeSH D13.695.667.138.382.300 – acyl coenzyme a MeSH D13.695.667.138.382.300.020 – acetyl coenzyme a MeSH D13.695.667.138.382.300.500 – malonyl coenzyme a MeSH D13.695.667.138.382.300.700 – palmitoyl coenzyme a MeSH D13.695.667.138.395 – cyclic amp MeSH D13.695.667.138.395.225 – 8-bromo cyclic adenosine monophosphate MeSH D13.695.667.138.395.250 – bucladesine MeSH D13.695.667.138.410 – deoxyadenine nucleotides MeSH D13.695.667.138.506 – flavin-adenine dinucleotide MeSH D13.695.667.138.694 – nad MeSH D13.695.667.138.749 – nadp MeSH D13.695.667.138.850 – phosphoadenosine phosphosulfate MeSH D13.695.667.138.925 – vidarabine phosphate MeSH D13.695.667.454 – guanine nucleotides MeSH D13.695.667.454.160 – cyclic gmp MeSH D13.695.667.454.160.325 – dibutyryl cyclic gmp MeSH D13.695.667.454.200 – deoxyguanine nucleotides MeSH D13.695.667.454.340 – guanosine diphosphate MeSH D13.695.667.454.340.350 – guanosine diphosphate sugars MeSH D13.695.667.454.340.350.400 – guanosine diphosphate fucose MeSH D13.695.667.454.340.350.500 – guanosine diphosphate mannose MeSH D13.695.667.454.440 – guanosine pentaphosphate MeSH D13.695.667.454.480 – guanosine tetraphosphate MeSH D13.695.667.454.504 – guanosine triphosphate MeSH D13.695.667.454.504.380 – guanosine 5'-o-(3-thiotriphosphate) MeSH D13.695.667.454.504.400 – guanylyl imidodiphosphate MeSH D13.695.667.454.525 – 5'-guanylic acid MeSH D13.695.667.454.700 – rna caps MeSH D13.695.667.454.700.710 – rna cap analogs MeSH D13.695.667.616 – inosine nucleotides MeSH D13.695.667.616.300 – cyclic imp MeSH D13.695.667.616.400 – inosine diphosphate MeSH D13.695.667.616.500 – inosine monophosphate MeSH D13.695.667.616.800 – inosine triphosphate
== Behavioral memory == As LTP is thought to underlie the processes of learning and memory, CaMKII is also crucial to memory formation. Behavioral studies involving genetically engineered mice have demonstrated the importance of CaMKII.
=== Key challenges === LEDs require optimized efficiency to hinge on ongoing improvements such as phosphor materials and quantum dots. The process of down-conversion (the method by which materials convert more-energetic photons to different, less energetic colors) also needs improvement. For example, the red phosphors that are used today are thermally sensitive and need to be improved in that aspect so that they do not color shift and experience efficiency drop-off with temperature. Red phosphors could also benefit from a narrower spectral width to emit more lumens and becoming more efficient at converting photons. In addition, work remains to be done in the realms of current efficiency droop, color shift, system reliability, light distribution, dimming, thermal management, and power supply performance. Early suspicions were that the LED droop was caused by elevated temperatures. Scientists showed that temperature was not the root cause of efficiency droop. The mechanism causing efficiency droop was identified in 2007 as Auger recombination, which was taken with mixed reaction. A 2013 study conclusively identified Auger recombination as the cause.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.